Making Montpellier a center of excellence and expertise in the field of biomarkers and 6P Medicine (Personalized, Preventive, Predictive, Participatory, Patient-Centered, Precise )

Optimizing the patient care pathway to develop the medicine and healthcare policies of tomorrow involves significant challenges. As we move forward, it is important to implement medical treatment that becomes progressively more predictive and personalized, from preventative measures to post-treatment follow-up. Targeted therapies are central to efficient medicine, with treatments adapted to the different subtypes of a given pathology via patient stratification, as well as to the complexity of each individual patient case by taking genetic, comorbidity, environmental, and epigenetic features into account. These advances rely heavily on biomarkers for diagnostic and prognostic approaches, and for optimal therapeutic decision-making.

Comprehensive patient data and biomarkers are both essential for confirming diagnosis as well as for determining pathology subtypes and establishing links with the disease progression or treatment response. These elements are the basis of numerous research projects across MUSE research fields, from fundamental research to clinical investigation.

To fully leverage relevant data, it is essential to develop new tools in bio-informatics and mathematics. Robust data analysis and interpretation will make it possible to validate and/or challenge physio-pathological hypotheses. That data is therefore a potential stimulus for new clinical, basic, and translational research.

The MUSE Biomarkers & Therapy key initiative (KIM) seeks to strengthen and support the links between clinical teams, academic research, and the socio-economic world to enable:

  • Emergence of new projects involving biomarkers and novel treatments, notably through MUSE support and labeling
  • Implementation of a new management system to retrieve clinical/biological data linked to retrospective and prospective bioresource collections, including standardization and interoperability among healthcare institutes to facilitate access to data
  • Participation in teaching modules dedicated to biomarkers and targeted therapy
  • Funding Master’s studentships, and fellowships for junior medical doctors (research year) on translational projects
  • Organization of events that bring together researchers, clinicians, and industry, meetings that are pivotal for setting up collaborations and promoting this sector

Leveraging the MUSE community of over 1,000 researchers, the Biomarkers & Therapy KIM is organized around:

MUSE research BioHealth Department

Three health care institutions

27 BioHealth research units

High-performance structures


This effort stems from one of seven regional priority innovation objectives in Health and Medicine of the Future. In the Occitanie region, these priorities are managed by project officers of the regional economic development agency AD’OCC.

It is integrated into the Montpellier Capital Santé (Montpellier France Health Hub) project’s objective to develop large-scale projects and strongly increase Montpellier Méditerranée Métropole visibility on a European scale.

It is also one of the priority axes of the Eurobiomed competitiveness cluster, which has been contributing to success and innovation in the regional health sector for over 10 years.